The telehealth company Hims & Hers Health is accelerating its international growth strategy, with a new launch in the United Kingdom marking its latest move. This follows closely on the heels of its ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Analysts are largely maintaining a "Hold" stance for now. The consensus average price target of $44.90 implies potential upside, but experts appear to be taking a wait-and-see approach. The key ...

Oppenheimer raised its target price to $675 from $615 after strong Q3 results, maintaining the stock as a top pick heading into 2026. The post Stocks Jump After Rate Cut: Market Analysis for December ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers.

Online telehealth company Hims and Hers Health is launching weight-loss membership and treatment plans in the UK. The new service will offer drugs such as Novo Nordisk's Wegovy and Eli Lilly's ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...